HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

4th Edition of World Congress on Infectious Diseases

June 21-22, 2023 | Rome, Italy

June 21 -22, 2023 | Rome, Italy
Infection 2023

Shem Sam

Speaker at World Congress on Infectious Diseases 2023 - Shem Sam
Lake Region Economic Bloc, Kenya
Title : Operational effectiveness of 1, 2, and 3 covid-19 vaccine doses against hospitalization of patients reporting for covid-19 test in west kenya



COVID-19 vaccines are administered to protect populations from SARS-CoV-2 infections. Even in case of breakthrough infections, current vaccines protect people against severe outcomes, that is, acute illness, hospitalization, and fatality. Prevention of patients from hospitalization can be an operational measure of effectiveness of subsequent vaccine doses. In this study we use Lake Region Economic Bloc –Kenya (LREB) health facility operational data to analyze protection offered by 1st, 2nd, and 3rd doses from hospitalization.


LREB facility data providers submitted vaccination data to Power BI supported dashboard from June 24, 2021 to July 30, 2022. In this regard data used in this paper is not experimental but operational. Vaccination data of patients was collected, visualized, and analyzed. By age the patients were 60 and above (4822), 40-60 (13190), 19-40 (27069), and 1-18 (8133).  In total 50,199 COVID-19 test entries were analyzed using R software: 0 dose, n=29919; 1 dose, n=4837; 2 doses, n=14389; and 3 doses, n=1054.


During the study period, out of 50,199 patients, 2,008 were admitted in various hospitals of which 392 (accounting for 19.5% of admissions) presented comorbidities. We observed hospitalization of  4.9%, 3.7%, 2.2%, and 1.9% of patients with 0, 1st, 2nd, and 3rd COVID-19 vaccine doses respectively.. We also found out that 74.5% of patients admitted in hospitals with comorbidities had zero doses. The proportion of patients admitted with comorbidities disaggregated by the number of doses received was as follows:  0 dose (10.7%); 1 dose (7.5%); 2 doses (3.1%); 3 doses (0.5%, only 3 admissions). The distribution of comorbidities and admissions were: pregnancy (144); cardiovascular disease (51); diabetes (53): hypertension (34); and HIV (27) patients.


The data used in this study is operational and biased towards patients who report for SARS-CoV-2 testing in public health facilities, either because of COVID-19 disease symptoms, or contacts, travel requirements or other reasons. It is not known which proportion of patients reported >1 times for testing. However, our operational data show that protection against symptoms and hospitalization increases with number of vaccine doses administered. These operational data confirm international literature on efficacy of COVID-19 vaccines in clinical trials.  We recommend targeted vaccinations of African risk groups, such as HIV patients, pregnant women, elderly, health workers.


Will be Updated Soon...